Journal Article Summary
The article reviews the use of oxybutynin extended release (ER) for managing overactive bladder (OAB), a condition that significantly affects patients' quality of life. OAB can lead to social withdrawal, depression, and decreased productivity due to symptoms like urgency and incontinence. Traditional treatments include behavioral therapies and medications, with oxybutynin being the first FDA-approved drug for OAB in 1975. However, the immediate release (IR) formulation of oxybutynin often caused bothersome side effects and required multiple daily doses, leading some patients to prefer living with their symptoms. The development of the ER formulation aimed to improve patient adherence by offering a once-daily dosing option while minimizing side effects.
The review summarizes various studies comparing oxybutynin ER to placebo and the IR formulation. Findings indicate that oxybutynin ER is effective in reducing urinary urge incontinence and has a lower incidence of dry mouth compared to the IR version. In clinical trials, patients taking oxybutynin ER reported significant improvements in their symptoms, with many achieving substantial reductions in incontinence episodes. However, the authors note that early studies had limitations, including small sample sizes and potential biases due to industry sponsorship, which may affect the reliability of the results.
Despite its benefits, the article highlights several limitations and safety concerns regarding oxybutynin ER, particularly in special populations like the elderly and children. Patients may experience side effects such as dry mouth and cognitive impairment, which are especially concerning for older adults who may already be taking multiple medications. The authors recommend that patients discuss their treatment options with healthcare professionals to weigh the benefits and risks of oxybutynin ER, particularly in the context of their overall health and any other medications they may be taking.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Arisco AM, Brantly EK, Kraus SR. Oxybutynin extended release for the management of overactive bladder: a clinical review. Drug design, development and therapy 2009. DOI: 10.2147/dddt.s3370. PMID: 19920931. PMCID: PMC2769230.
Featured Pill Pals Product
Oxybutynin 5 mg Immediate Release Tablets --- Generic For Ditropan --- KVK Tech
Oxybutynin 5 mg Immediate Release Tablets — Generic For Ditropan — KVK Tech is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
